Aeglea Biotherapeutics (AGLE) tech validated on Roche's deal to acqurie rival TL1A program for $7.1B - Stifel
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $23.00 price target on Aeglea Biotherapeutics (NASDAQ: AGLE), saying Roche's deal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
